araag2/HINT huggingface dataset:
Clinical trial NCT01065454 (phase 2, status: active, not recruiting)
Conditions: hypertension, pulmonary, ventricular dysfunction, left
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1
Drugs: riociguat (adempas, bay63-2521), riociguat (adempas, bay63-2521), riociguat (adempas, bay63-2521), placebo
SMILES: COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, COC(=O)N(C)C1=C(N)N=C(N=C1N)C1=NN(CC2=C(F)C=CC=C2)C2=C1C=CC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients with symptomatic pulmonary hypertension due to left
             ventricular systolic dysfunction despite optimized heart failure therapy

        Exclusion Criteria:

          -  Types of pulmonary hypertension other than group 2.1 of Dana Point Classification
Clinical trial NCT01596062 (phase 2, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: simulect®, neoral®, certican®, myfortic®, corticosteroids
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Patients receiving a primary renal graft from a deceased or living, related or
             unrelated donor and who require basiliximab induction therapy

          -  Cold ischemia time < 30 hours

        Exclusion (Non inclusion) criteria:

          -  Patients undergoing multi-organ transplantation, including both kidneys, or who have
             previously undergone organ transplantation, including renal transplantation

          -  Patients receiving a graft from a non-heart-beating donor

          -  A-B-O incompatible graft or positive T cell crossmatch

          -  Patients receiving a graft from an expanded criteria donor according to the UNOS
             definition (donor older than 60 years or donor aged between 50 and 60 years and
             presence of at least 2 of the following factors: hypertension, serum creatinine
             concentration ≥ 132 µmol/mL, cardiovascular cause of death)

          -  Positive anti-HLA antibodies (Luminex) prior to transplantation

          -  Patients whose original renal disease was primary focal and segmental hyalinosis or
             was related to atypical hemolytic uremic syndrome

          -  EBV-negative patients receiving a graft from an EBV-positive donor (EBV D+R-)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01261494 (phase 2, status: completed)
Conditions: type ii diabetes mellitus
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: gft505 80mg, placebo
SMILES: CSC1=CC=C(C=C1)C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or post-menopausal female (defined as >12 months since last menstrual period) or
             surgical menopause. If hormonal replacement therapy, it should be stable at least for
             6 months prior to screening.

          -  Body Mass Index ≥27 and ≤45 kg/m².

          -  Drug-Naive patients with type 2 diabetes mellitus (non insulin dependent diabetes).
             Patients should not be treated by insulin or other diabetes medication for the last 3
             months prior to screening. Patients treated for less than 4 weeks with insulin may be
             included in the study.

          -  HbA1c ≥ 7.0% and <9.5%.

          -  Antibody glutamate decarboxylase acid (Anti-GAD) negative for patients aged less than
             40 years.

        Exclusion Criteria:

          -  Type I Diabetes Mellitus.

          -  Blood Pressure > 160 / 95 mmHg.

          -  Lipid-lowering drugs such as fibrates.

          -  Fasting Plasma Glucose (FPG) ≥ 240 mg/dL.

          -  Triglycerides (TG) > 400 mg/dL.
Clinical trial NCT00427466 (phase 2, status: completed)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: pemetrexed
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastasized or locally inoperable soft tissue sarcoma

          -  Progression or relapse after previous cytostatic treatment with adriamycin and/or an
             ifosfamide containing chemotherapeutic substance

          -  Two-dimensionally measurable/evaluable tumor parameters (according to WHO-criteria)

          -  Previous radiotherapy is acceptable as long as the irradiated area does not include
             the only measurable lesion

          -  Patient compliance and geographic proximity, which ensure the possibility of adequate
             Follow-up

          -  Life expectancy of more than 3 months

          -  ECOG <= 2

          -  Age at least 18 years

          -  Adequate bone marrow function at the initiation of therapy

          -  Adequate kidney function

          -  Patient consent

          -  Patient ability to consent

        Exclusion Criteria:

          -  Previous or concurrent irradiation of the indicator lesion

          -  Other concomitant tumor therapy

          -  Severe impairment in hepatic function

          -  Active Infection

          -  Previous treatment with Pemetrexed

          -  Second tumor within the past 5 years (excepting basal cell carcinoma, adequately
             treated carcinoma in situ of the uterine cervix, of the bladder urothelium or colon
             polyps including pTis and pTin)

          -  Severely symptomatic cardiovascular and cerebrovascular disease

          -  HIV, active Hepatitis B or C

          -  Dementia, Cerebral stroke with cognitive deficits

          -  Kidney function <= 79 ml/min (calculated according to MDRD): Inability to interrupt
             treatment with NSAIDs/ASS/Cox-2 Inhibitors 2 days prior to and following
             administration of Pemetrexed. If a patient is taking an NSAID or salicylate with a
             long half-life it should not be taken five days prior to, on the day of or two days
             after application of Pemetrexed. Low dose acetyl salicylic acid administration is
             permitted (e.g. 100 mg/die.) There are no restrictions with kidney function greater
             than 80 ml/min.

          -  Inability or unwillingness to take folic acid, vitamin B12 or dexamethasone

          -  Pleural or pericardial exudate, ascites without a drain (3rd Space)

          -  Time Interval from the last course of chemotherapy < 4 weeks

          -  Symptomatic CNS-Metastases

          -  Gravidity or Lactation

          -  Women of reproductive age without reliable contraception if not the following applies:
             Must be surgically sterile, postmenopausal, or compliant with a medically approved
             contraceptive regimen during and for 3 months after treatment

          -  Positive serum or urine pregnancy test

          -  Participation in another trial at the same time
Clinical trial NCT01309659 (phase 2, status: terminated)
Conditions: anemia, unexplained anemia (uae)
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: iron sucrose, iron sucrose
SMILES: O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O, O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Reason stopped: 
    lack of enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 65 years old

          -  Hemoglobin concentration ≥ 9.0 g/dL and < 11.5 g/dL (women) or < 12.7 g/dL (men)

          -  Unexplained anemia

          -  Serum ferritin level ≥ 20 and ≤ 200 ng/mL

          -  Able to walk without the use of a walker, motorized device or the assistance of
             another person.

          -  Able to understand and willing to provide written informed consent in the absence of
             dementia

          -  Must be able to understand and speak in English

        Exclusion Criteria:

          -  Red blood cell transfusions within the past 3 months

          -  Use of erythropoiesis stimulating agents (ESA) in the past 3 months

          -  Intravenous Iron Infusions within the past 3 months

          -  Distance on baseline 6MWT (6 minute walk test) above the median for age and sex

          -  History of unstable angina or myocardial infarction in the past 3 months

          -  History of stroke or TIA (transient ischemic attack) the past 3 months

          -  Uncontrolled hypertension (diastolic blood pressure > 100 mm Hg or systolic blood
             pressure > 160 mm Hg on 2 separate occasions)

          -  Positive fecal occult blood test within the screening period

          -  Elevated AST (aspartate aminotransferase) or ALT (alanine aminotransferase) ≥ 2x upper
             limit of normal

          -  Documented anaphylactic reaction to iron sucrose infusion in the past

          -  Subjects initiated on oral iron supplementation within the last 6 weeks, or those
             initiated on oral iron within the last 3 months who have had at least a one gram/dL
             improvement in Hb since starting oral iron supplementation
Clinical trial NCT00606593 (phase 2, status: completed)
Conditions: chronic primary insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: act-078573 oral capsules at 25 and 100 mg and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo, act-078573 and matching placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Elderly subjects (> 64 years) with a diagnosis of primary insomnia.

        Exclusion Criteria:

          -  History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental
             Disorders IV (DSM-IV) axis I disorder other than primary insomnia.

          -  Sleep apnea, or restless legs syndrome.

          -  Daytime napping of more than 1 hour per day.

          -  Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2
             years prior to the screening visit.

          -  Unwillingness to refrain from drugs, over-the-counter or herbal medication having an
             effect on sleep or behavior.
Clinical trial NCT00089921 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: scio-469, scio-469, placebo, scio-469
SMILES: [H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1, [H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(C)CN(C(=O)C2=C(Cl)C=C3N(C)C=C(C(=O)C(=O)N(C)C)C3=C2)[C@]([H])(C)CN1CC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients having active rheumatoid arthritis who are not receiving medications known as
             hepatotoxic disease-modifying anti-rheumatic drugs (DMARDs)

          -  Patients taking hydroxychloroquine (Plaquenil) must be on a stable or consistent dose
             prior to entering study

        Exclusion Criteria:

          -  Patients using Enbrel, Remicade, Kineret, Humira, or an experimental biologic agent
             within the past 3 months

          -  Lab tests revealed elevated liver enzymes within the past 6 months

          -  Medical history of Tuberculosis, cancer, multiple sclerosis, neuropathy or
             encephalopathy

          -  HIV positive

          -  Abnormal electrocardiogram

          -  Chronic or acute infection
Clinical trial NCT00326625 (phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: 40 mg glatiramer acetate, placebo
SMILES: CC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of definite or probable ALS in accordance with the El-Escorial criteria.

          2. Subject has experienced his/her first ALS symptoms within 3 years prior to the
             screening visit.

          3. Slow VC test equal or greater than 70% of the predicted value.

          4. The sum of the 3 respiratory items on the ALSFRS-R must total at least 10 points.

          5. Stable dose of riluzole for at least 8 weeks prior to screening.

          6. Age - 18-70 (inclusive).

        Exclusion Criteria:

          1. The use of invasive or non-invasive ventilation.

          2. Subject having undergone gastrostomy.

          3. Subject with any clinically significant or unstable medical condition.

          4. Subjects participating in any other clinical trial (within 12 weeks prior to screening
             and thereafter).

          5. Additional criteria per protocol.
Clinical trial NCT00678015 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: nordihydroguaiaretic acid (ndga)
SMILES: C[C@@H](CC1=CC(O)=C(O)C=C1)[C@H](C)CC1=CC(O)=C(O)C=C1
Reason stopped: 
    per protocol - interim analysis showed no significant psa declines among the first 12 patients
    after 3 cycles of treatment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Rising prostate-specific antigen (PSA) value after local therapy with a PSA doubling
             time (PSADT) between 6 and 24 months (four or more readings at least two weeks apart
             within the last six months)

          -  Prior definitive therapy for prostate cancer consisting of one of the following:

               1. External beam radiotherapy with or without hormone therapy

               2. Brachytherapy with or without pelvic external beam radiation or hormone therapy

               3. Radical prostatectomy with or without adjuvant or salvage radiation therapy

          -  PSA > 1 ng/ml, which has risen serially on two determinations at least one week apart

          -  Progressive disease by "Phoenix" consensus definition for patients who have undergone
             primary radiation therapy (PSA nadir + 2 ng/mL)

          -  No metastatic disease

          -  Prior adjuvant or neoadjuvant androgen deprivation is permitted, provided:

               1. > 6 months since last day of effective androgen deprivation

               2. Testosterone > 250 ng/dL

               3. Patient is not on intermittent androgen deprivation

          -  Karnofsky performance status (KPS) of > 70%

          -  Liver Function Tests are within normal range

          -  Glycated hemoglobin (HgA1c) < 6%

          -  Patients must be four weeks from major surgery or radiotherapy to be eligible

        Exclusion Criteria:

          -  Presence of another active malignancy other than prostate cancer, or treated
             squamous/basal cell carcinoma of the skin. Concomitant medical condition which would
             make it undesirable, in the physician's opinion, for the patient to participate in the
             protocol or would jeopardize compliance with the protocol requirements

          -  Diabetes mellitus, unless diet-controlled

          -  Must be off saw palmetto, pomegranate juice, finasteride, or any herbal agent intended
             to lower PSA for > 4 weeks. Baseline PSADT calculation must occur off of these agents

          -  Patients may not have evidence of local-only recurrence of prostate cancer

          -  No history of liver disease, including Hepatitis B or C, alcoholic liver disease, or
             autoimmune liver disease. A prior history of Hepatitis A is allowed provided that
             baseline liver function tests are within normal limits

          -  Patients with castration resistant prostate cancer are ineligible (prostate cancer
             which has progressed on androgen deprivation therapy with a Luteinizing
             hormone-releasing hormone (LHRH)-agonist or orchiectomy)
Clinical trial NCT01160419 (phase 2, status: unknown status)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: docetaxel 50 mg/m2, 1-hour-infusion, day 1, oxaliplatin 85 mg/m², 2-hour-infusion, day 1, folinic acid 200 mg/m², 1-2-hour-infusion, day 1, 5-fu 2600 mg/m², 24-hour-infusion, day 1
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically Confirmed Adenocarcinoma of the Gastroesophageal Junction (AEG I-III)
             or Gastric Adenocarcinoma (every T, N+ or T3/T4, Nx, M0)

          -  Written Informed Consent

          -  Age ≥ 18 Years

          -  Expected operability

          -  ECOG ≤ 2

          -  Exclusion of Peritoneal Metastasis

          -  Adequate Hematological, Renal, Cardiac and Hepatic Function

          -  Effective Contraception

        Exclusion Criteria:

          -  Prior Chemotherapy or Radiotherapy of the Adenocarcinoma of the Gastroesophageal
             Junction (AEG I-III) or Gastric Adenocarcinoma

          -  Not Histologically Confirmed Primary Tumor

          -  Distant Metastasis, Local Relapse

          -  Known Hypersensitivity for 5-Fluorouracil, Leucovorin, Oxaliplatin or Docetaxel

          -  Known Dihydropyrimidin-Dehydrogenase (DPD) - Deficiency

          -  Peripheral Polyneuropathy ≥ Grade II (NCI-CTCAE, Version 3.0)

          -  Myocardial Infarction in the last 3 Months, Cardiac Insufficiency Grade II-IV (NYHA)

          -  Severe Comorbidity or Acute Infections

          -  Pregnancy or Breast Feeding

          -  Insufficient Contraception

          -  Participation in another Clinical Trial (Simultaneously or 30 Days Prior to
             Enrollment)

          -  Malignancy <5 years (except: Carcinoma In Situ of the Cervix Uteri or Adequately
             Treated Basalioma of the Skin)

          -  Lack of Legal Capacity
Clinical trial NCT00439634 (phase 2, status: terminated)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: ave1625, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    following a pre-specified interim analysis and data monitoring committee recommendation due to
    insufficient level of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with diagnosis of schizophrenia (diagnosed ≤ 35 years of age).

          -  Current treatment consisting exclusively of olanzapine, risperidone/paliperidone,
             quetiapine or aripiprazole monotherapy for at least 2 months.

        Exclusion Criteria:

          -  Inpatient hospitalization within past 3 months.

          -  Residence at the current address < 3 months due to any instability in the disease.

          -  Presence of depressive symptoms.

          -  Past history of clinically significant violent behavior.

          -  Substance dependence or abuse.

          -  Pregnant or breast-feeding women or women not protected by effective contraceptive
             method of birth control.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00115193 (phase 2, status: completed)
Conditions: non-hodgkin's lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: pegfilgrastim, pegfilgrastim
SMILES: CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1, CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria: - Histologically proven mantle cell lymphoma or histologically proven
        diffuse large B-cell non-Hodgkin's lymphoma (NHL) according to the REAL classification -
        Measurable and/or evaluable disease - Previously untreated patients Exclusion Criteria: -
        Burkitt's or B-lymphoblastic lymphoma - Central nervous system (CNS) involvement - Active
        infection requiring treatment with systemic anti-infectives within 72 hours of chemotherapy
        - Prior malignancy within the last 5 years - T-cell lymphoma or history of indolent
        lymphoma - Prior bone marrow or stem cell transplantation - Known sensitivity to E. coli
        derived drug products